Cell Death & Disease:WFDC2能够抑制前列腺癌的转移

2020-07-26 AlexYang MedSci原创

WFDC2是一个小分子分泌蛋白,在卵巢癌中已有广泛的研究。之前的研究已经证实WFDC2能够促进卵巢癌的增殖和转移,并且可作为诊断生物标记。然而,WFDC2在前列腺癌中的特定功能还未报道。

WFDC2是一个小分子分泌蛋白,在卵巢癌中已有广泛的研究。之前的研究已经证实WFDC2能够促进卵巢癌的增殖和转移,并且可作为诊断生物标记。然而,WFDC2在前列腺癌中的特定功能还未报道。

最近,有研究人员通过生物信息学方法筛选了诊断标记,并发现了良好的预后因子WFDC2。在前列腺癌中,WFDC2的表达于格林森评分和转移呈现负相关关系。体内和体外试验中,WFDC2的过表达和添加重组蛋白HE4能够显著的抑制前列腺癌的转移。免疫共沉淀和共定位试验证明了WFDC2能够结合到上皮生长因子受体(EFGR)的细胞外区域。免疫印迹实验表明WFDC2过表达和添加重组蛋白HE4能够去激活EGFR/AKT/GSK3B/Snail信号途径,之后抑制上皮-间质转化过程。

最后,研究人员指出,他们的研究鉴定了肿瘤抑制子WFDC2能够通过去激活EGFR信号来抑制前列腺癌的转移。

原始出处:

Yaoyi Xiong, Lushun Yuan, Song Chen et al. WFDC2 suppresses prostate cancer metastasis by modulating EGFR signaling inactivation. Cell Death & Disease. 16 July 2020

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1962156, encodeId=9b85196215622, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jun 09 17:17:06 CST 2021, time=2021-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871858, encodeId=246418e18589b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Dec 07 01:17:06 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013427, encodeId=88ab201342e6f, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Apr 01 07:17:06 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531649, encodeId=4db11531649a6, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Tue Jul 28 03:17:06 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040790, encodeId=dd5c1040e90c7, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Jul 26 15:17:06 CST 2020, time=2020-07-26, status=1, ipAttribution=)]
    2021-06-09 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1962156, encodeId=9b85196215622, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jun 09 17:17:06 CST 2021, time=2021-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871858, encodeId=246418e18589b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Dec 07 01:17:06 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013427, encodeId=88ab201342e6f, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Apr 01 07:17:06 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531649, encodeId=4db11531649a6, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Tue Jul 28 03:17:06 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040790, encodeId=dd5c1040e90c7, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Jul 26 15:17:06 CST 2020, time=2020-07-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1962156, encodeId=9b85196215622, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jun 09 17:17:06 CST 2021, time=2021-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871858, encodeId=246418e18589b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Dec 07 01:17:06 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013427, encodeId=88ab201342e6f, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Apr 01 07:17:06 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531649, encodeId=4db11531649a6, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Tue Jul 28 03:17:06 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040790, encodeId=dd5c1040e90c7, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Jul 26 15:17:06 CST 2020, time=2020-07-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1962156, encodeId=9b85196215622, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jun 09 17:17:06 CST 2021, time=2021-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871858, encodeId=246418e18589b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Dec 07 01:17:06 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013427, encodeId=88ab201342e6f, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Apr 01 07:17:06 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531649, encodeId=4db11531649a6, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Tue Jul 28 03:17:06 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040790, encodeId=dd5c1040e90c7, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Jul 26 15:17:06 CST 2020, time=2020-07-26, status=1, ipAttribution=)]
    2020-07-28 cy0328
  5. [GetPortalCommentsPageByObjectIdResponse(id=1962156, encodeId=9b85196215622, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jun 09 17:17:06 CST 2021, time=2021-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871858, encodeId=246418e18589b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Dec 07 01:17:06 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013427, encodeId=88ab201342e6f, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Apr 01 07:17:06 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531649, encodeId=4db11531649a6, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Tue Jul 28 03:17:06 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040790, encodeId=dd5c1040e90c7, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Jul 26 15:17:06 CST 2020, time=2020-07-26, status=1, ipAttribution=)]
    2020-07-26 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Eur Urol:根治性前列腺癌切除术后前列腺癌结节复发的抢救性淋巴结清除术的长期结果

前列腺癌(PCa)结节复发患者进行抢救性淋巴结清除术(sLND)治疗的长期结果仍旧未知。最近,有研究人员在一个多中心的群体中调查了sLND后的长期肿瘤治疗结果。

Brit J Cancer:使用剪接寡核苷酸靶向ERG致瘤基因来治疗前列腺癌的研究

ERG致瘤基因是ETS转录因子家族的一个成员,是前列腺癌的遗传驱使因子。在50%的案例中通过与雄激素响应的TMPRSS2启动子融合被激活。因此,在开发靶向ERG的药物上研究较热。最近,有研究人员通过反

Prostate:前列腺癌男性患者前列腺中阿托伐他汀的进入途径和浓度

他汀类药物对前列腺癌在体外和体内都有抗癌作用。目前尚不清楚这是由于全身性降胆固醇还是直接抑制前列腺局部生长。他汀类药物能否进入前列腺也不清楚,理论上,亲脂性的他汀类药物可以通过被动扩散的方式通过富含脂

Prostate Cancer P D:前列腺癌检测的种族差异

Stockholm3测试改善了≥2格林森等级分组(GG≥2)前列腺癌的检测,然而,在具有临床实践模式和种族差异的美国群体中还尚未有评估。最近,有研究人员鉴定了不同种族亚群中PC风险情况,并

European Urology:局限性高级别前列腺癌中PSA水平无法线性预测患者预后

前列腺癌是一种雄激素高度依赖的肿瘤,对雄激素剥夺治疗(androgen deprivation therapy, ADT)非常敏感,前列腺特异性抗原(prost

Cancer:PLCO中前列腺癌总转移和进展率

前列腺、肺、结肠直肠和卵巢(PLCO)癌症筛查试验评估了前列腺特异性抗原筛查和数字直肠检查对前列腺癌死亡率的影响。另一个研究终点是总转移性疾病的负担。